Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmune Bio Inc (NQ: INMB )

9.480 +0.110 (+1.17%)
Streaming Delayed Price Updated: 9:33 AM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inmune Bio Inc

< Previous 1 2 Next >
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open... 
From INmune Bio, Inc.
Via GlobeNewswire
What to Know About the Future of Cancer Treatment
Via StatePoint Media
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
From INmune Bio, Inc.
Via GlobeNewswire
BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC
Via Investor Brand Network
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
From INmune Bio, Inc.
Via GlobeNewswire
BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer
Via Investor Brand Network
Exposures Product Safety
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
From INmune Bio, Inc.
Via GlobeNewswire
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.